{"pmid":32490726,"title":"Thromboinflammatory response in SARS-CoV-2 sepsis.","text":["Thromboinflammatory response in SARS-CoV-2 sepsis.","Viral sepsis is rare, and its real incidence is not known. SARS-CoV-2 infection causes the release of a significant amount of pro-inflammatory cytokines that aggravates interstitial pneumonia and evolves in viral sepsis with prominent hypercoagulability. We believe it is useful and advisable to establish early immunomodulator therapy and the prophylaxis anticoagulant therapy should be rethought.","Med Leg J","Maiese, Aniello","Passaro, Giovanna","Matteis, Alessandra DE","Fazio, Valentina","Raffaele, La Russa","Paolo, Marco Di","32490726"],"abstract":["Viral sepsis is rare, and its real incidence is not known. SARS-CoV-2 infection causes the release of a significant amount of pro-inflammatory cytokines that aggravates interstitial pneumonia and evolves in viral sepsis with prominent hypercoagulability. We believe it is useful and advisable to establish early immunomodulator therapy and the prophylaxis anticoagulant therapy should be rethought."],"journal":"Med Leg J","authors":["Maiese, Aniello","Passaro, Giovanna","Matteis, Alessandra DE","Fazio, Valentina","Raffaele, La Russa","Paolo, Marco Di"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32490726","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1177/0025817220926915","keywords":["sars-cov-2","sepsis, covid-19, thrombosis, coagulopathy"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668623433562324992,"score":9.490897,"similar":[{"pmid":32311318,"pmcid":"PMC7164875","title":"SARS-CoV-2 and viral sepsis: observations and hypotheses.","text":["SARS-CoV-2 and viral sepsis: observations and hypotheses.","Since the outbreak of coronavirus disease 2019 (COVID-19), clinicians have tried every effort to understand the disease, and a brief portrait of its clinical features have been identified. In clinical practice, we noticed that many severe or critically ill COVID-19 patients developed typical clinical manifestations of shock, including cold extremities and weak peripheral pulses, even in the absence of overt hypotension. Understanding the mechanism of viral sepsis in COVID-19 is warranted for exploring better clinical care for these patients. With evidence collected from autopsy studies on COVID-19 and basic science research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV, we have put forward several hypotheses about SARS-CoV-2 pathogenesis after multiple rounds of discussion among basic science researchers, pathologists, and clinicians working on COVID-19. We hypothesise that a process called viral sepsis is crucial to the disease mechanism of COVID-19. Although these ideas might be proven imperfect or even wrong later, we believe they can provide inputs and guide directions for basic research at this moment.","Lancet","Li, Hui","Liu, Liang","Zhang, Dingyu","Xu, Jiuyang","Dai, Huaping","Tang, Nan","Su, Xiao","Cao, Bin","32311318"],"abstract":["Since the outbreak of coronavirus disease 2019 (COVID-19), clinicians have tried every effort to understand the disease, and a brief portrait of its clinical features have been identified. In clinical practice, we noticed that many severe or critically ill COVID-19 patients developed typical clinical manifestations of shock, including cold extremities and weak peripheral pulses, even in the absence of overt hypotension. Understanding the mechanism of viral sepsis in COVID-19 is warranted for exploring better clinical care for these patients. With evidence collected from autopsy studies on COVID-19 and basic science research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV, we have put forward several hypotheses about SARS-CoV-2 pathogenesis after multiple rounds of discussion among basic science researchers, pathologists, and clinicians working on COVID-19. We hypothesise that a process called viral sepsis is crucial to the disease mechanism of COVID-19. Although these ideas might be proven imperfect or even wrong later, we believe they can provide inputs and guide directions for basic research at this moment."],"journal":"Lancet","authors":["Li, Hui","Liu, Liang","Zhang, Dingyu","Xu, Jiuyang","Dai, Huaping","Tang, Nan","Su, Xiao","Cao, Bin"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311318","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/S0140-6736(20)30920-X","topics":["Diagnosis","Mechanism"],"weight":1,"_version_":1666138491136770048,"score":97.3645},{"pmid":32339221,"title":"COVID-19 and its implications for thrombosis and anticoagulation.","text":["COVID-19 and its implications for thrombosis and anticoagulation.","The SARS-CoV-2 coronavirus (COVID-19) induced infection can be associated with a coagulopathy, findings consistent with infection induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury which can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen degradation products, while abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19 associated coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and standard supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiology, and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full intensity anticoagulation doses unless otherwise clinically indicated. Even though there is an associated coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, standard guidelines for the management of DIC and bleeding should be followed.","Blood","Connors, Jean Marie","Levy, Jerrold H","32339221"],"abstract":["The SARS-CoV-2 coronavirus (COVID-19) induced infection can be associated with a coagulopathy, findings consistent with infection induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury which can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen degradation products, while abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19 associated coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and standard supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiology, and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full intensity anticoagulation doses unless otherwise clinically indicated. Even though there is an associated coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, standard guidelines for the management of DIC and bleeding should be followed."],"journal":"Blood","authors":["Connors, Jean Marie","Levy, Jerrold H"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339221","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1182/blood.2020006000","locations":["multiorgan"],"topics":["Treatment"],"weight":1,"_version_":1666138494210146304,"score":92.88315},{"pmid":32393985,"title":"Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study.","text":["Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study.","Sepsis is a life-threatening complication of pneumonia, including coronavirus disease-2019 (COVID-19)-induced pneumonia. Evidence of the benefits of vitamin C (VC) for the treatment of sepsis is accumulating. However, data revealing the targets and molecular mechanisms of VC action against sepsis are limited. In this report, a bioinformatics analysis of network pharmacology was conducted to demonstrate screening targets, biological functions, and the signaling pathways of VC action against sepsis. As shown in network assays, 63 primary causal targets for the VC action against sepsis were identified from the data, and four optimal core targets for the VC action against sepsis were identified. These core targets were epidermal growth factor receptor (EGFR), mitogen-activated protein kinase-1 (MAPK1), proto-oncogene c (JUN), and signal transducer and activator of transcription-3 (STAT3). In addition, all biological processes (including a top 20) and signaling pathways (including a top 20) potentially involved in the VC action against sepsis were identified. The hub genes potentially involved in the VC action against sepsis and interlaced networks from the Kyoto Encyclopedia of Genes and Genomes Mapper assays were highlighted. Considering all the bioinformatic findings, we conclude that VC antisepsis effects are mechanistically and pharmacologically implicated with suppression of immune dysfunction-related and inflammation-associated functional processes and other signaling pathways. These primary predictive biotargets may potentially be used to treat sepsis in future clinical practice.","Brief Bioinform","Li, Rong","Guo, Chao","Li, Yu","Qin, Zuqian","Huang, Wenjun","32393985"],"abstract":["Sepsis is a life-threatening complication of pneumonia, including coronavirus disease-2019 (COVID-19)-induced pneumonia. Evidence of the benefits of vitamin C (VC) for the treatment of sepsis is accumulating. However, data revealing the targets and molecular mechanisms of VC action against sepsis are limited. In this report, a bioinformatics analysis of network pharmacology was conducted to demonstrate screening targets, biological functions, and the signaling pathways of VC action against sepsis. As shown in network assays, 63 primary causal targets for the VC action against sepsis were identified from the data, and four optimal core targets for the VC action against sepsis were identified. These core targets were epidermal growth factor receptor (EGFR), mitogen-activated protein kinase-1 (MAPK1), proto-oncogene c (JUN), and signal transducer and activator of transcription-3 (STAT3). In addition, all biological processes (including a top 20) and signaling pathways (including a top 20) potentially involved in the VC action against sepsis were identified. The hub genes potentially involved in the VC action against sepsis and interlaced networks from the Kyoto Encyclopedia of Genes and Genomes Mapper assays were highlighted. Considering all the bioinformatic findings, we conclude that VC antisepsis effects are mechanistically and pharmacologically implicated with suppression of immune dysfunction-related and inflammation-associated functional processes and other signaling pathways. These primary predictive biotargets may potentially be used to treat sepsis in future clinical practice."],"journal":"Brief Bioinform","authors":["Li, Rong","Guo, Chao","Li, Yu","Qin, Zuqian","Huang, Wenjun"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32393985","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/bib/bbaa079","keywords":["immune dysfunction","inflammation","network pharmacology","sepsis","vitamin c"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666627828069695489,"score":92.584854},{"pmid":32426897,"title":"Heparin - an old drug with multiple potential targets in Covid-19 therapy.","text":["Heparin - an old drug with multiple potential targets in Covid-19 therapy.","A prominent clinical feature of severe Covid-19 infection is respiratory failure associated with pulmonary coagulopathy. Recent reports published in Thrombosis and Haemostasis show that treatment with low-molecular weight heparin (LMWH) decreases mortality in critically ill patients with sepsis-induced hypercoagulation, and thus argue for prophylactic administration of the anticoagulant. In addition, the authors point to non-anticoagulant activities of heparin, in particular anti-inflammatory effects with potential to prevent deterioration of the disease. We would like to use this opportunity to clarify the biochemical background of the diverse activities of heparin, and further, how this information may be exploited to generate more efficient treatment of the viral infection. Mechanisms to consider relate to the functional roles of proteins interacting with heparan sulfate (HS), a polysaccharide closely related to heparin.","J Thromb Haemost","Lindahl, Ulf","Li, Jin-Ping","32426897"],"abstract":["A prominent clinical feature of severe Covid-19 infection is respiratory failure associated with pulmonary coagulopathy. Recent reports published in Thrombosis and Haemostasis show that treatment with low-molecular weight heparin (LMWH) decreases mortality in critically ill patients with sepsis-induced hypercoagulation, and thus argue for prophylactic administration of the anticoagulant. In addition, the authors point to non-anticoagulant activities of heparin, in particular anti-inflammatory effects with potential to prevent deterioration of the disease. We would like to use this opportunity to clarify the biochemical background of the diverse activities of heparin, and further, how this information may be exploited to generate more efficient treatment of the viral infection. Mechanisms to consider relate to the functional roles of proteins interacting with heparan sulfate (HS), a polysaccharide closely related to heparin."],"journal":"J Thromb Haemost","authors":["Lindahl, Ulf","Li, Jin-Ping"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426897","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jth.14898","locations":["heparin","heparin","Heparin"],"e_drugs":["Heparin","Polysaccharides","Heparitin Sulfate","Heparin, Low-Molecular-Weight"],"topics":["Treatment"],"weight":1,"_version_":1667252837926567937,"score":90.92063},{"pmid":32468151,"title":"The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?","text":["The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?","The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response.","Inflamm Res","Bellinvia, Salvatore","Edwards, Christopher J","Schisano, Matteo","Banfi, Paolo","Fallico, Matteo","Murabito, Paolo","32468151"],"abstract":["The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response."],"journal":"Inflamm Res","authors":["Bellinvia, Salvatore","Edwards, Christopher J","Schisano, Matteo","Banfi, Paolo","Fallico, Matteo","Murabito, Paolo"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468151","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00011-020-01366-6","keywords":["checkpoint inhibitors","covid-19","cytokine storm","immune dysregulation","inflammatory receptors","sepsis"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887162912768,"score":90.28669}]}